

## Evaluating the Roles of Tyrosine 3.60 and the “DRY” Ionic Lock in $\beta$ 2 Adrenoceptor Internalisation

CM Ashley, ND Holliday University of Nottingham, Nottingham, UK

Many studies support an “ionic lock” that stabilises the inactive conformation of class A GPCRs (Rovati *et al.*, 2007; Valentin-Hansen *et al.*, 2012). Thus in the  $\beta$ 2-adrenoceptor ( $\beta$ 2AR), Arg3.50 of the “DRY” motif, at the cytoplasmic end of transmembrane domain (TM) III, has been proposed to form a salt bridge with TM VI Glu 6.30 (Valentin-Hansen *et al.*, 2012). However these direct contacts between TM III and VI residues are not evident for most inactive GPCR crystal structures (Rasmussen *et al.*, 2007; Warne *et al.*, 2008). Instead adrenoceptor structures indicate another residue, Tyr3.60 in intracellular loop 2, might partner either Arg3.50 ( $\beta$ 1AR, Warne *et al.*, 2008) or Glu6.30 ( $\beta$ 2AR, Rasmussen *et al.*, 2007). Hence this study investigated effects of Tyr3.60, Arg3.50 and Glu6.30 mutants on agonist-stimulated  $\beta$ 2AR internalisation, as one indicator of receptor activation.

SNAP-tagged  $\beta$ 2AR cDNAs were constructed and stably expressed in HEK293 cells as described (2). Cells on 96 well plates were first labelled with SNAPsurface AF488 (0.1  $\mu$ M, NEB) to identify  $\beta$ 2AR initially at the cell surface (Valentin-Hansen *et al.*, 2012). Agonist treatments (45 min, 37°C) were in HBSS / 0.1% BSA and 5  $\mu$ g/ml AF633-transferrin (Tf, Invitrogen). Following fixation, images were acquired using an IX Micro platereader (Molecular Devices) and automated image analysis (MetaXpress 2.0) quantified the intensity of labelled  $\beta$ 2AR within Tf-identified internal compartments. Individual concentration response curves in triplicate were pooled to obtain pEC<sub>50</sub> and R<sub>max</sub> values (Graphpad Prism).

$\beta$ 2AR wild type (wt) and mutants were predominantly cell surface expressed under basal conditions and underwent isoprenaline-stimulated internalisation (10  $\mu$ M responses ( $n = 2-6$ ): 1.64 $\pm$ 0.10 fold over basal (wt), 1.39 $\pm$ 0.05 (Y3.60A), 1.57 $\pm$ 0.11 (E6.30A) and 1.38 (R3.50A)). Salbutamol and salmeterol were partial agonists in stimulating  $\beta$ 2AR wt internalisation, relative to isoprenaline (Table 1). E6.30A substitution resulted in significantly increased potency and relative R<sub>max</sub> for all three agonists, and a modest increase in pEC<sub>50</sub> values was also evident in the R3.50A mutant (Table 1). However compared to wt responses, isoprenaline and salbutamol were 3-7 less potent in stimulating  $\beta$ 2AR Y3.60A endocytosis, while salmeterol was inactive (Table 1). Thus contrasting effects of Y3.60A and E6.30A in the internalisation assay support a role for Glu6.30 but not Tyr3.60 in constraining an inactive  $\beta$ 2AR conformation. However Tyr3.60 may support active complexes (e.g. with arrestins) necessary for  $\beta$ 2AR endocytosis.

**Table 1** Summary of  $\beta$ 2AR internalisation responses

Receptor	Isoprenaline		Salbutamol		Salmeterol	
	pEC <sub>50</sub>	R <sub>max</sub> (%)	pEC <sub>50</sub>	R <sub>max</sub> (%)	pEC <sub>50</sub>	R <sub>max</sub> (%)
WT	7.43 $\pm$ 0.17	100	6.72 $\pm$ 0.21	53.5 $\pm$ 6.3	7.73 $\pm$ 0.41	31.4 $\pm$ 18.0
E6.30A	8.53 $\pm$ 0.24* *	100	7.63 $\pm$ 0.20*	88.7 $\pm$ 13.4	8.90 $\pm$ 0.18*	106 $\pm$ 17*
R3.50A	8.10	100	7.17	87.6	8.28	41.8
Y3.60A	6.90 $\pm$ 0.11	100	5.90 $\pm$ 0.49	28.9 $\pm$ 12.7	N.D.	-1.7 $\pm$ 10.1

Pooled data (3-6 expts, except R3.50A, n=2).  $R_{\max}$  is expressed as maximum response relative to 10  $\mu\text{M}$  Isoprenaline at the same receptor. N.D. not determined. \* $P < 0.05$ , \*\* $P < 0.01$  compared to wt (Student's  $t$ -test).

We thank Louise Valentin-Hansen and Prof Thue Schwartz (University of Copenhagen) for provision of cDNAs. Clare Ashley was an undergraduate Wellcome Trust Vacation Scholar.

Rasmussen SG *et al.* (2007) *Nature* **450**: 383 - 387.

Rovati GE *et al.* (2007) *Mol. Pharmacol.* **71**: 959 - 964.

Valentin-Hansen L *et al.* (2012) *J. Biol. Chem.* **287**: 31973 - 31982.

Warne T *et al.* (2008) *Nature* 454: 486 – 491..